New Delhi, Jul 20: India has taken a landmark step in its fight against dengue with the approval of Takeda’s QDENGA (TAK‑003) by the Central Drugs Standard Control Organisation (CDSCO).

This marks the country’s first licensed dengue vaccine, offering hope against a disease that has become one of India’s most pressing seasonal health threats.

About QDENGA

QDENGA is a live‑attenuated tetravalent vaccine developed by Japanese pharmaceutical company Takeda. It is designed to protect against all four dengue virus serotypes (DENV‑1, DENV‑2, DENV‑3, DENV‑4). Administered as two subcutaneous doses three months apart, the vaccine stimulates immunity to reduce symptomatic dengue and severe disease requiring hospitalisation.

Unlike the older Dengvaxia, QDENGA does not require prior blood testing to confirm past infection, simplifying mass vaccination programmes.

Also read: Dogs to Sniff Out Cancer! Inside Bengaluru Startup Dognosis’ Bold AI Experiment

Significance for India

India carries nearly one‑third of the global dengue burden, with cases rising more than eleven‑fold in the past two decades.

Seasonal outbreaks during monsoon months overwhelm hospitals, relying until now on mosquito control, breeding site elimination, personal protection, early diagnosis, and supportive treatment. The availability of a vaccine adds a crucial preventive tool to India’s arsenal.

Who Can Receive It?

Internationally, QDENGA has been approved for children and adults, regardless of prior dengue infection. This feature is a major advantage over Dengvaxia, which is restricted to individuals with documented past infection.

Indian prescribing guidelines will be detailed at launch, but the vaccine’s broad eligibility could streamline rollout.

Effectiveness

Evidence from the pivotal TIDES Phase III trial, involving over 20,000 children and adolescents across eight endemic countries, demonstrated strong long‑term protection. After 4.5 years of follow‑up, QDENGA showed:

• 84% protection against dengue‑related hospitalisation
• 61% protection against virologically confirmed dengue overall
• Sustained protection against severe dengue in both seropositive and seronegative individuals

Effectiveness varied by serotype, but results were robust enough to earn WHO recommendation and approvals in more than 40 countries, including the EU, UK, Brazil, Indonesia, and Argentina.

Cost and Availability

Pricing in India has not yet been announced. However, Takeda’s partnership with Hyderabad‑based Biological E to manufacture up to 50 million doses annually is expected to reduce costs and ensure supply.

Whether the vaccine is initially available only in private markets or later incorporated into government immunisation programmes will influence affordability. More clarity is expected closer to launch.

Will Everyone Need It?

Not necessarily. WHO recommends dengue vaccination as part of an integrated strategy that includes mosquito control, community awareness, early diagnosis, access to healthcare, and surveillance.

Vaccination is not a substitute for preventing mosquito bites or eliminating breeding sites, but it can significantly reduce severe illness and hospitalisation.

Possibility of Dengue’s Elimination

No vaccine alone can eradicate dengue. Multiple virus serotypes circulate simultaneously, and mosquito populations continue to expand due to climate change and urbanisation.

Experts stress that vaccination must complement existing public health measures rather than replace them.

Conclusion

The approval of QDENGA represents a milestone in India’s dengue response. If widely adopted, it could ease hospital pressure during outbreaks, reduce severe cases, and save lives.

Local manufacturing positions India as a global hub for dengue vaccine supply. Yet, continued surveillance, vector control, and public awareness remain essential to curb transmission.

India’s first dengue vaccine offers a powerful new tool against a disease that affects millions annually.

While questions around pricing, rollout, and inclusion in public programmes remain, QDENGA’s ability to protect against all four serotypes without prior infection testing makes it a potentially transformative addition to India’s dengue prevention strategy.